证券代码：688526 证券简称：科前生物 公告编号：2025-014 武汉科前生物股份有限公司 第四届监事会第八次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性依 法承担法律责任。 一、监事会会议召开情况 武汉科前生物股份有限公司（下称"公司"）于 2025 年 4 月 25 日以现场表决的形式召开第四届监事会第八次会议（下称"本次会 议"）。本次会议通知于 2025 年 4 月 15 日以邮件、电话的方式向各 位监事发出，本次会议由监事会主席吴斌先生主持，本次会议应参与 表决监事 3 人，实际参与表决监事 3 人。本次会议的召集、召开程序 均符合《公司法》《证券法》等法律、法规和规范性文件以及《公司 章程》的规定。 二、监事会会议审议情况 经与会监事审议，作出决议如下： 本议案尚需提交 2024 年年度股东大会审议。 （二）审议通过《关于<公司 2024 年年度报告>及其摘要的议案》 监事会在全面审阅公司 2024 年年度报告及摘要后，发表意见如 下： （1）公司 2024 年年度报告的编制和审核程序符合相关法律法规 和公 ...

证券代码：688526 证券简称：科前生物 公告编号：2025-015 本次利润分配以实施权益分派股权登记日登记的总股本扣减 武汉科前生物股份有限公司（以下简称"公司"）回购专用证券账户 中的股份为基数，具体日期将在权益分派实施公告中明确。 在实施权益分派的股权登记日前公司总股本发生变动的，则以 未来实施分配预案的股权登记日的总股本扣减公司回购专用证券账 户中的股份数为基数，拟维持分配总额不变，相应调整每股分配比例， 并将另行公告具体调整情况。 公司未触及《上海证券交易所科创板股票上市规则》第 12.9.1 条第一款第（八）项规定的可能被实施其他风险警示的情形。 本次利润分配预案尚需提交 2024 年年度股东大会审议。 1 一、利润分配预案内容 经华兴会计师事务所（特殊普通合伙）审计，武汉科前生物股份 有限公司（下称"公司"）2024 年度归属于母公司所有者的净利润 为 382,350,180.06 元，截止 2024 年 12 月 31 日，公司母公司报表期 末未分配利润为 2,124,329,905.89 元。经董事会决议，公司 2024 年 度利润分配预案如下： 武汉科前生物股份有限公司 关于 2024 ...

Dividend and Share Repurchase - The company plans to distribute a cash dividend of 4.3 CNY per 10 shares, totaling approximately 199.48 million CNY (including tax) based on a total share capital of 463,916,483 shares after accounting for repurchased shares[6]. - The total amount for cash dividends and share repurchases in 2024 is approximately 234.24 million CNY, which represents 61.26% of the net profit attributable to shareholders[6]. - The cash dividend distribution will not involve capital reserve transfers or bonus shares for this year[6]. - The company has implemented a share repurchase amounting to approximately 34.76 million CNY during the year[6]. - The cash dividends and repurchased shares amount to 199.48 million CNY (including tax), accounting for 52.17% of the net profit attributable to shareholders[6]. - The company has not conducted any capital increase through capital reserves or issued bonus shares in the current year[6]. Financial Performance - The company's operating revenue for 2024 was CNY 941,923,862.86, a decrease of 11.48% compared to CNY 1,064,074,588.89 in 2023[21]. - Net profit attributable to shareholders for 2024 was CNY 382,350,180.06, down 3.43% from CNY 395,934,947.68 in 2023[21]. - The net profit after deducting non-recurring gains and losses was CNY 311,886,194.33, a decline of 15.82% from CNY 370,515,885.08 in 2023[21]. - The cash flow from operating activities for 2024 was CNY 392,681,812.32, a decrease of 27.02% compared to CNY 538,033,929.89 in 2023[21]. - Basic earnings per share for 2024 were CNY 0.82, down 3.53% from CNY 0.85 in 2023[22]. - Total assets at the end of 2024 were CNY 4,495,821,916.06, a decrease of 3.76% from CNY 4,671,249,471.01 at the end of 2023[21]. - The net assets attributable to shareholders at the end of 2024 were CNY 3,940,969,701.00, an increase of 2.75% from CNY 3,835,627,197.55 at the end of 2023[21]. Research and Development - The R&D expenditure as a percentage of operating revenue increased to 9.14% in 2024 from 8.32% in 2023[22]. - The company is building a new biological product R&D platform, which includes mRNA vaccine and recombinant adenovirus vector vaccine platforms, laying a solid foundation for future vaccine development[36]. - The company has upgraded its vaccine production processes to be more automated and intelligent, significantly improving product quality and reducing costs[37]. - The company is exploring new protein sources for animal feed, collaborating with key laboratories to develop a system for large-scale insect protein production from organic waste[39]. - The company has established an AI synthetic biology innovation platform to enhance vaccine design and development efficiency, significantly improving product R&D outcomes[40]. - The company has made significant advancements in vaccine technology, including heat-resistant protective agents and high-efficiency purification processes, ensuring high safety and immunogenicity[43][44]. - The company has established multiple advanced technology platforms, including pathogen and epidemiology research, gene editing, and mRNA vaccine development, to enhance its R&D capabilities[63]. Market and Industry Trends - The veterinary biological products industry in China achieved a sales revenue of 16.276 billion yuan in 2023, with a production value of 17.667 billion yuan and a gross profit of 9.352 billion yuan, resulting in an average gross margin of 57.46%[54]. - The market for veterinary biological products has grown from 13.292 billion yuan in 2018 to 16.276 billion yuan in 2023, reflecting a compound annual growth rate of 4.13%[54]. - The sales of non-mandatory immunization veterinary biological products increased from 40% in 2015 to 68.18% in 2023, indicating a significant market shift[57]. - The company is strategically expanding its market presence and product offerings to enhance its competitive edge in the veterinary biological products industry[42]. Governance and Compliance - The company has established a governance structure in compliance with the Company Law and Securities Law, ensuring effective decision-making and risk control[169]. - The board of directors consists of 9 members, including 3 independent directors, who fulfill their duties diligently and in accordance with the company's articles of association[170]. - The supervisory board, comprising 3 members, effectively oversees the company's operations and internal control systems, reducing operational risks[171]. - The company maintains a clear separation from its controlling shareholder in terms of business, assets, and finances, ensuring independent operation[172]. - The company has implemented various information disclosure and investor relations management systems to ensure timely and accurate communication with investors[171]. Employee and Management - The company reported a total of 924 employees, with 821 in the parent company and 103 in major subsidiaries[199]. - The employee composition includes 263 production personnel, 162 sales personnel, 353 technical personnel, 17 financial personnel, and 129 administrative personnel[199]. - The company has established a salary structure based on position and performance, with monthly performance pay distributed according to monthly evaluations[200]. - The company has implemented employee benefits including five social insurances and one housing fund, meal subsidies, and health check-ups to attract and retain talent[200]. Future Outlook - The company provided an optimistic outlook, projecting a revenue growth of 25% for the next fiscal year, targeting $1.875 billion[178]. - New product launches are expected to contribute an additional $200 million in revenue, with a focus on innovative technology solutions[178]. - The company plans to invest CNY 287.14 million from its fundraising into a new project for the construction of a high-level animal vaccine industrialization base[102]. - The company aims to accelerate the launch of seven new products, including vaccines for swine and poultry, to enhance market competitiveness[160].

Financial Performance - The company's revenue for Q1 2025 was CNY 245,188,828.52, representing a 19.65% increase compared to CNY 204,929,240.40 in the same period last year[3]. - Net profit attributable to shareholders was CNY 108,236,874.48, up 24.08% from CNY 87,228,395.78 year-over-year[3]. - Basic and diluted earnings per share increased by 27.78% to CNY 0.23 from CNY 0.18 in the previous year[4]. - Total operating revenue for Q1 2025 reached ¥245,188,828.52, an increase of 19.5% compared to ¥204,929,240.40 in Q1 2024[19]. - Net profit for Q1 2025 was ¥107,786,272.75, representing a 23.5% increase from ¥87,075,680.66 in Q1 2024[20]. - The company's total comprehensive income for Q1 2025 was ¥123,142,728.35, compared to ¥90,397,978.13 in Q1 2024, an increase of 36.3%[21]. Assets and Liabilities - The total assets at the end of the reporting period were CNY 4,639,554,478.66, a 3.20% increase from CNY 4,495,821,916.06 at the end of the previous year[4]. - The company's current assets reached CNY 2,581,193,766.69, up from CNY 2,473,078,015.08, indicating an increase of about 4.4%[15]. - The company's total liabilities increased to ¥574,464,302.84 in Q1 2025, compared to ¥552,798,705.10 in Q1 2024, reflecting a growth of 3.1%[17]. - The total equity attributable to shareholders rose to ¥4,063,487,267.59 in Q1 2025, up from ¥3,940,969,701.00 in Q1 2024, marking an increase of 3.1%[17]. Cash Flow - The cash flow generated from operating activities was CNY 140,037,835.33, reflecting a 5.22% increase from CNY 133,086,579.74 in the same period last year[4]. - The cash inflow from operating activities for Q1 2025 showed a positive trend, indicating improved liquidity and operational efficiency[22]. - In Q1 2025, the cash inflow from operating activities was $315,702,694.25, an increase of 14.2% compared to $276,340,855.26 in Q1 2024[23]. - The net cash flow from operating activities for Q1 2025 was $140,037,835.33, up from $133,086,579.74 in Q1 2024, reflecting a growth of 5.4%[24]. - The cash outflow from financing activities in Q1 2025 was $1,105,814.69, compared to $177,480,673.80 in Q1 2024, showing a reduction of 99.4%[24]. Research and Development - Research and development expenses totaled CNY 21,330,798.19, accounting for 8.70% of revenue, down from 9.68% in the previous year[4]. - The company has committed to ongoing research and development to enhance its product offerings and market position[4]. - The company invested a total of 12,186,716.38 yuan in the research of the swine pseudorabies gene engineering live vaccine, achieving new veterinary drug registration[11]. - The company has established a cooperation research and development management system with Huazhong Agricultural University, ensuring competitive negotiation for future projects[10]. - The company is actively engaged in the research and development of various vaccines and diagnostic kits, with multiple products in different stages of clinical trials and registrations[12][13]. Shareholder Information - The largest shareholder, Wuhan Huazhong Agricultural University, holds 16.73% of the shares[9]. - The second-largest shareholder, Chen Huan Chun, holds 15.20% of the shares[9]. - The total number of ordinary shareholders at the end of the reporting period was 7,968[8]. - The company has not reported any changes in the participation of major shareholders in margin trading and securities lending[10].

招商证券股份有限公司 关于武汉科前生物股份有限公司 2024 年度募集资金存放与实际使用情况的专项核查意见 招商证券股份有限公司（以下简称"招商证券"或"保荐机构"）作为武汉 科前生物股份有限公司（以下简称"科前生物"或"公司"）首次公开发行股票 的保荐机构，根据《证券发行上市保荐业务管理办法》《上海证券交易所股票科 创板上市规则》《上市公司监管指引第 2 号——上市公司募集资金管理和使用的 监管要求》以及《上海证券交易所科创板上市公司自律监管指引第 1 号——规范 运作》等有关规定，对科前生物 2024 年度募集资金存放与实际使用情况进行了 审慎核查，核查意见如下： 一、募集资金基本情况 （一）实际募集资金金额、资金到位时间 根据中国证券监督管理委员会出具的《关于同意武汉科前生物股份有限公司 首次公开发行股票注册的批复》（证监许可(2020)1909 号），并经上海证券交易 所同意，公司由主承销商招商证券采用向战略投资者定向配售、网下向符合条件 的投资者询价配售和网上向持有上海市场非限售 A 股股份和非限售存托凭证市 值的社会公众投资者定价发行相结合的方式，发行了普通股（A 股）股票 10,500.00 万 ...

华兴会计师事务所(特殊普通合伙) 武汉科前生物股份有限公司 2024 年度募集资金存放与实际使用情况的 专项鉴证报告 华兴专字[2025]24014440030 号 您可使用手机"扫一扫"或进入"注册会计师行业统一些管理会 兴会计师事务所(特殊普通合伙 ING CERTIFIED PUBLIC ACCOUNTANT Rlock R. 152 Hudong Road Fuzhou Fujian China 申话(Tel):0591-87852 武汉科前生物股份有限公司 2024年度募集资金存放与实际使用情况的 专项鉴证报告 华兴专字[2025]24014440030号 武汉科前生物股份有限公司全体股东: 我们接受委托,对后附的武汉科前生物股份有限公司(以下简称"科前生 物")董事会编制的《2024年度募集资金存放与实际使用情况的专项报告》(以 下简称"专项报告")执行了合理保证的鉴证业务。 一、董事会的责任 头会计师事务所(特殊普通台 C CERTIFIED PUBLIC ACCOUNT 按照《上市公司监管指引第 2 号 -- 上市公司募集资金管理和使用的监 管要求》和《上海证券交易所科创板上市公司自律监管指引 ...

Investment Rating - The report maintains a "Recommended" investment rating for the industry, suggesting a potential upside of over 15% relative to benchmark indices [4]. Core Insights - The swine industry shows stable breeding profits, with a focus on capacity reduction logic. The average price of external three yuan pigs was 15.0 CNY/kg, up 2.1% week-on-week, while the average weight of pigs sold was 128.6 kg, down 0.2% [19][20]. - The beef industry is at an inflection point, with strong price performance continuing. The average price of calves was 28.2 CNY/kg, up 2.1%, and the average price of fattened cattle was 25.8 CNY/kg, up 0.7% [23][30]. - The white chicken market is affected by ongoing avian influenza, with significant impacts on breeding stock and prices. The average price of white feather broiler chicks was 2.8 CNY/chick, up 9.5% [31][34]. - The animal health sector is seeing a recovery in demand as breeding supply stabilizes, with a notable increase in the issuance of vaccines [48][49]. Summary by Sections Swine Industry - The average price of external three yuan pigs was 15.0 CNY/kg, reflecting a week-on-week increase of 2.1%. The average weight of pigs sold was 128.6 kg, down 0.2%. The price of 15 kg external three yuan piglets was 668 CNY/head, with a slight decrease of 0.05% [19][21]. - Supply pressure remains stable, with normal sales rhythms from large producers and limited sales from smallholders. The demand side shows increased activity from secondary breeding, but overall consumption remains weak [20][21]. - The report recommends companies such as Muyuan Foods, Wens Foodstuff Group, and New Hope Liuhe for investment [20]. Beef Industry - The beef breeding industry is entering a capacity release phase, with the earliest signs of a price bottom forming. The report anticipates a potential recovery in the industry by late 2025 or early 2026 [23][30]. - The average wholesale price of beef was 61.4 CNY/kg, reflecting a slight increase of 0.2% [29][30]. - Recommended companies include Fucheng Co. and Guangming Meat Industry, focusing on integrated breeding and sales [23]. Poultry Industry - The average price of white feather broiler eggs was 1.6 CNY/egg, up 2.0%, while the average price of white feather broilers was 3.7 CNY/kg, up 2.2% [31][34]. - The report highlights the impact of avian influenza on breeding imports, particularly from the U.S. and New Zealand, which has been suspended for over three months [31][32]. - Recommended companies include Yisheng Livestock and He Feng Food [31]. Animal Health Sector - The demand for animal health products is expected to recover as breeding supply stabilizes. The issuance of vaccines has shown significant increases, particularly for swine diseases [48][49]. - The report recommends companies like Kexin Biological and Zhongmu Biotechnology, which are positioned to benefit from the recovery in the animal health market [49].

今日涨跌幅居前的概念板块 | 概念 | 今日涨跌幅（%） | 概念 | 今日涨跌幅（%） | | --- | --- | --- | --- | | 供销社 | 3.93 | 中国AI 50 | -2.09 | | 跨境支付(CIPS) | 3.65 | 人形机器人 | -1.59 | | 草甘膦 | 3.57 | 英伟达概念 | -1.48 | | 中韩自贸区 | 3.16 | 同花顺果指数 | -1.38 | | 自由贸易港 | 3.05 | 算力租赁 | -1.32 | | 统一大市场 | 2.74 | 液冷服务器 | -1.28 | | 数字货币 | 2.63 | 华为手机 | -1.22 | | 转基因 | 2.62 | AI手机 | -1.21 | | 信托概念 | 2.33 | MLOps概念 | -1.21 | | 电子身份证 | 2.04 | 太赫兹 | -1.21 | 资金面上看，今日转基因概念板块获主力资金净流入0.60亿元，其中，7股获主力资金净流入，5股主力 资金净流入超千万元，净流入资金居首的是神农种业，今日主力资金净流入8224.06万元，净流入资金 居前的还有大北农、敦煌种业、 ...

Investment Rating - The report maintains a "Recommended" rating for the agriculture, forestry, animal husbandry, and fishery industry [1] Core Views - The report highlights the weak fluctuation of pig prices, with expectations of a downward trend in the short term and a long-term weak operation in 2025 due to increased supply and weak demand [4][14] - The poultry sector may see price improvements due to the impact of tariffs and a shortage of quality breeding stock caused by avian influenza [5][28] - The animal health sector is expected to benefit from improved downstream demand and external expansion opportunities, with rising prices for key products like Tylosin [6][41] - The planting sector is experiencing price fluctuations for major grains, with a focus on the commercialization of genetically modified seeds [8][46] - The feed sector is seeing a decline in prices, with recommendations for companies like Haida Group [8][49] - The pet market continues to grow rapidly, with strong performance from domestic brands and recommendations for companies in the pet food and medical sectors [8][54][57] Summary by Sections Pig Industry - Pig prices are expected to adjust slightly, with a forecast of weak performance in 2025 due to increased supply [4][14] - As of April 10, 2025, the average price of live pigs is 14.6 CNY/kg, with no change from the previous week [14] Poultry Industry - The poultry sector may see price increases due to tariff impacts and a lack of quality breeding stock [5][28] - The average price of broiler chickens is 3.75 CNY/lb, reflecting a weekly increase [28] Animal Health - The animal health sector is experiencing improved profitability, with Tylosin prices rising significantly [6][41] - The report suggests focusing on companies with expected external expansion, such as Reap Bio [6] Planting Sector - Major grain prices are fluctuating, with corn priced at 2199 CNY/ton and wheat at 2422 CNY/ton [8][46] - The report recommends companies involved in genetically modified seed development [8] Feed Sector - Feed prices are declining, with pig feed at 3.35 CNY/kg [8][49] - The report suggests focusing on companies like Haida Group due to expected industry consolidation [8] Pet Industry - The pet market is projected to reach 300.2 billion CNY in 2024, with a growth rate of 7.5% [8][54] - Recommendations include companies like Guobao Pet and Zhongchong Co., which are experiencing significant growth [8][57]

证券代码：688526 证券简称：科前生物 武汉科前生物股份有限公司 2025 年员工持股计划 二〇二五年四月 武汉科前生物股份有限公司 2025 年员工持股计划 声明 本公司及全体董事、监事保证本员工持股计划及其摘要不存在虚假记载、误 导性陈述或重大遗漏，并对其真实性、准确性、完整性承担个别和连带的法律责 任。 本员工持股计划所有持有人承诺，若公司因信息披露文件中有虚假记载、误 导性陈述或者重大遗漏，导致不符合解锁安排的，持有人应当自相关信息披露文 件被确认存在虚假记载、误导性陈述或者重大遗漏后，将由本员工持股计划所获 得的全部利益返还公司。 1 武汉科前生物股份有限公司 2025 年员工持股计划 风险提示 一、有关本员工持股计划的具体资金来源、出资比例、实施方案等属初步结 果，能否完成实施，存在不确定性。 二、若员工认购资金较低，则本员工持股计划存在不能成立的风险；若员工 认购资金不足，本员工持股计划存在低于预计规模的风险。 三、公司后续将根据规定披露相关进展情况，敬请广大投资者谨慎决策，注 意投资风险。 2 武汉科前生物股份有限公司 2025 年员工持股计划 特别提示 一、武汉科前生物股份有限公司（以下 ...